These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15287079)

  • 1. Quantile estimation following non-parametric phase I clinical trials with ordinal response.
    Paul RK; Rosenberger WF; Flournoy N
    Stat Med; 2004 Aug; 23(16):2483-95. PubMed ID: 15287079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
    Ivanova A; Wang K
    Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential designs for logistic phase I clinical trials.
    Liu G; Rosenberger WF; Haines LM
    J Biopharm Stat; 2006; 16(5):605-21. PubMed ID: 17037261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.
    Doussau A; Thiébaut R; Paoletti X
    Stat Med; 2013 Dec; 32(30):5430-47. PubMed ID: 24018535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose finding with longitudinal data: simpler models, richer outcomes.
    Paoletti X; Doussau A; Ezzalfani M; Rizzo E; Thiébaut R
    Stat Med; 2015 Sep; 34(22):2983-98. PubMed ID: 26109523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved up-and-down designs for phase I trials.
    Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD
    Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some notable properties of the standard oncology Phase I design.
    Hather GJ; Mackey H
    J Biopharm Stat; 2009; 19(3):543-55. PubMed ID: 19384695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential designs for ordinal phase I clinical trials.
    Liu G; Rosenberger WF; Haines LM
    Biom J; 2009 Apr; 51(2):335-47. PubMed ID: 19358220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.
    van Brummelen EM; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
    J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):235-42. PubMed ID: 26960536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A two-dimensional biased coin design for dual-agent dose-finding trials.
    Sun Z; Braun TM
    Clin Trials; 2015 Dec; 12(6):596-607. PubMed ID: 26163309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A web application for evaluating Phase I methods using a non-parametric optimal benchmark.
    Wages NA; Varhegyi N
    Clin Trials; 2017 Oct; 14(5):553-557. PubMed ID: 28649874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
    He W; Liu J; Binkowitz B; Quan H
    Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An adaptive model switching approach for phase I dose-finding trials.
    Daimon T; Zohar S
    Pharm Stat; 2013; 12(4):225-32. PubMed ID: 23801550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Stat Med; 2011 Jul; 30(17):2070-80. PubMed ID: 21344472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isotonic designs for phase I trials.
    Leung DH; Wang Y
    Control Clin Trials; 2001 Apr; 22(2):126-38. PubMed ID: 11306151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivariate isotonic design for dose-finding with ordered groups.
    Ivanova A; Wang K
    Stat Med; 2006 Jun; 25(12):2018-26. PubMed ID: 16220476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.